The cost-effectiveness of abobotulinumtoxinA (Dysport) and onabotulinumtoxinA (Botox) for managing spasticity of the upper and lower limbs, and cervical dystonia

References

• Mugglestone M, Eunson P, Murphy M. Spasticity in children and young people with non-progressive brain disorders: summary of NICE guidance. BMJ. 2012;345:e4845.
   PubMedGoogle Scholar
• Olver J, Esquenazi A, Fung VS, et al. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. Eur J Neurol. 2010;17(Suppl 2):57–73.
   PubMed Web of Science ®Google Scholar
• Rawicki B, Sheean G, Fung VS, et al. Botulinum toxin assessment, intervention and aftercare for paediatric and adult niche indications including pain: international consensus statement. Eur J Neurol. 2010;17(Suppl 2):122–134.
   PubMedGoogle Scholar
• Sheean G, Lannin NA, Turner-Stokes L, et al. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol. 2010;17(Suppl 2):74–93.
   PubMed Web of Science ®Google Scholar
• Mayo Clinic. Cervical dystonia. 2021. [cited 2021 Jun 22]. https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123?lang=en.
   Google Scholar
• Yelnik AP, Simon O, Bensmail D, et al. Drug treatments for spasticity. Ann Phys Rehabil Med. 2009;52(10):746–756.
   PubMedGoogle Scholar
• Brin MF, Comella CL, Jankovic J, et al. Long-term treatment with botulinum toxin type a in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23(10):1353–1360.
   PubMed Web of Science ®Google Scholar
• Dysport powder for solution for injection. 2020. [cited 2020 Oct 12]. https://www.medicines.org.uk/emc/product/7261/smpc.
   Google Scholar
• Botox powder for solution for injection. 2020. [cited 2020 Oct 12]. https://www.medicines.org.uk/emc/product/859/smpc.
   Google Scholar
• Brockmann K, Schweitzer K, Beck G, et al. Comparison of different preparations of botulinum toxin a in the treatment of cervical dystonia. Neurol Asia. 2012;17(2):115–119.
   Web of Science ®Google Scholar
• Jacinto J, Ashford S, Fheodoroff K, et al. Real-life data on the time to retreatment with botulinum toxin a in upper limb spasticity management. World Congress for NeuroRehabilitation, 2020; October 7–11 Virtual Congress.
   Google Scholar
• Danchenko N, Delgado D, Haeussler K, et al. PND10 indirect treatment comparison of botulinum toxins a for the treatment of pediatric upper limb spasticity. Value Health. 2020;23(Suppl 1):S260.
   PubMedGoogle Scholar
• Guyot P, Kalyvas C, Mamane C, et al. Botulinum toxins type A (BoNT-A) in the management of lower limb spasticity in children: a systematic literature review and bayesian network Meta-analysis. J Child Neurol. 2019;34(7):371–381.
   PubMed Web of Science ®Google Scholar
• Andringa A, van de Port I, van Wegen E, et al. Effectiveness of botulinum toxin treatment for upper limb spasticity poststroke over different ICF domains: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2019;100(9):1703–1725.
   PubMed Web of Science ®Google Scholar
• Baker J, Pereira G. The efficacy of botulinum toxin a for spasticity and pain in adults: a systematic review and meta-analysis using the grades of recommendation, assessment, development and evaluation approach. Clin Rehabil. 2013;27(12):1084–1096.
   PubMed Web of Science ®Google Scholar
• Fu X, Wang Y, Wang C, et al. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network Meta-analysis. Clin Rehabil. 2018;32(6):713–721.
   PubMed Web of Science ®Google Scholar
• Danchenko N, Johnston KM, Haeussler K, et al. Comparative efficacy, safety, and cost-effectiveness of abobotulinumtoxinA and onabotulinumtoxinA in children with upper limb spasticity: a systematic literature review, indirect treatment comparison, and economic evaluation. J Med Econ. 2021;24(1):949–961.
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Ashforda S, Jacintod J, et al. Economic outcomes in real-world use of botulinum toxin-A products for adult patients with upper limb spasticity: a UK perspective. Paper presented at: TOXINS 2021; January 16–17, 2021.
   Google Scholar
• Schwabe AL. Botulinum roxin in the treatment of pediatric upper limb spasticity. Semin Plast Surg. 2016;30(1):24–28.
   PubMed Web of Science ®Google Scholar
• Turner-Stokes L, Ashford S, Fheodoroff K, et al. The GAS-eous tool: goal attainment scaling - evaluation of outcome for upper-limb spasticity. 2013. https://www.kcl.ac.uk/cicelysaunders/resources/tools/gas-eous
   Google Scholar
• Turner-Stokes L, Jacinto J, Fheodoroff K, et al. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: findings from the prospective, observational upper limb international spasticity (ULIS-III) cohort study. J Rehabil Med. 2021;53(2):jrm00157.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Danchenko N, Lundkvist J. PND34 resource use related to cervical dystonia, pediatric lower limb spasticity and adult upper limb spasticity in the UK: a physician questionnaire. Value Health. 2020;23(Suppl 1):S265.
   Google Scholar
• Jost WH, Hefter H, Stenner A, et al. Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy. J Neural Transm. 2013;120(3):487–496.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. 2013. https://www.nice.org.uk/process/pmg9/chapter/the-reference-case.
   Google Scholar
• Misra VP, Ehler E, Zakine B, et al. Factors influencing response to botulinum toxin type a in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open. 2012;2(3):e000881.
   PubMed Web of Science ®Google Scholar
• Jacinto J, Ashford S, Fheodoroff K, et al. Factors associated with favorable response in real-world use of botulinum toxin a products for adult patients with upper limb spasticity. TOXINS 2022; July 27–30, 2022, New Orleans, LA.
   Google Scholar
• Schnitzler A, Danchenko N, Lundkvist J, et al. PND13 network meta-analysis for botulinum toxin a for the treatment of adult lower limb spasticity (ALLS) in post-stroke population. Value Health. 2020;23:S260.
   PubMed Web of Science ®Google Scholar
• Bjornson K, Hays R, Graubert C, et al. Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation. Pediatrics. 2007;120(1):49–58.
   PubMed Web of Science ®Google Scholar
• Delgado MR, Tilton A, Russman B, et al. AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: a randomized controlled trial. Pediatrics. 2016;137(2):1–9.
   Web of Science ®Google Scholar
• Fehlings D, Narayanan U, Andersen J, et al. Botulinum toxin-A use in paediatric hypertonia: Canadian practice patterns. Can J Neurol Sci. 2012;39(4):508–515.
   PubMed Web of Science ®Google Scholar
• NHS England. National Tariff 2019/20: Non-mandatory prices. 2019. https://www.england.nhs.uk/publication/national-tariff-payment-system-documents-annexes-and-supporting-documents/
   Google Scholar
• Gracies J-M, Francisco G, Jech R, et al. The effect of guided self-rehabilitation contracts combined with simultaneous injections of abobotulinumtoxinA into upper and lower limbs on voluntary movements in adults with spastic hemiparesis. IPMDS International Congress; Sept 24, 2019, Nice, France.
   Google Scholar
• British National Formulary [Internet]. British Medical Association and Royal Pharmaceutical Society of Great Britain. 2020. [cited 2020 Jan 10]. https://bnf.nice.org.uk/.
   Google Scholar
• NHS Improvement. 2017/18 Reference costs: national schedule of reference costs. 2020.
   Google Scholar
• Curtis L, Burns A. Unit costs of health and social care 2019. Canterbury (UK): University of Kent; 2019.
   Google Scholar
• Doan QV, Brashear A, Gillard PJ, et al. Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. Pm R. 2012;4(1):4–10.
   PubMedGoogle Scholar
• Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil. 2008;89(5):799–806.
   PubMed Web of Science ®Google Scholar
• Moore P. Cost-effectiveness analysis on dysport: a focus on early intervention to improve barefoot walking speed. Value Health. 2021;24:S160.
   Web of Science ®Google Scholar
• Deighton A, Johnston K, Dabirvaziri P, et al. Acute migraine medication and medication overuse headache: a systematic literature review. Paper presented at: American Headache Society Annual Scientific Meeting 2020, Virtual.
   Google Scholar
• Khan KA, Petrou S, Rivero-Arias O, et al. Mapping EQ-5D utility scores from the PedsQL generic core scales. Pharmacoeconomics. 2014;32(7):693–706.
   PubMed Web of Science ®Google Scholar
• Hilker R, Schischniaschvili M, Ghaemi M, et al. Health related quality of life is improved by botulinum neurotoxin type a in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001;71(2):193–199.
   PubMed Web of Science ®Google Scholar
• Chang E, Ghosh N, Yanni D, et al. A review of spasticity treatments: pharmacological and interventional approaches. Crit Rev Phys Rehabil Med. 2013;25(1–2):11–22.
   PubMedGoogle Scholar
• CEA Registry. 2020. [cited 2020 Sep 8]. http://healtheconomicsdev.tuftsmedicalcenter.org/cear2/search/search.aspx.
   Google Scholar
• Matza LS, Deger KA, Vo P, et al. Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. Qual Life Res. 2019;28(9):2359–2372.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Slejko JF, Mark J, et al. Catalogue of EQ-5D scores for the United Kingdom. Med Decis Making. 2011;31(6):800–804.
   PubMed Web of Science ®Google Scholar
• Ward A, Roberts G, Warner J, et al. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. J Rehabil Med. 2005;37(4):252–257.
   PubMed Web of Science ®Google Scholar
• Al-Mazraawy B. Potential cost savings were identified across the Yale Health System when primarily using DysportVR vs. BotoxVR. 53rd Annual ASHP Midyear Clinical Meeting; 2018, Anaheim, CA.
   Google Scholar
• Dursun N, Akarsu M, Gokbel T, et al. Switching from onabotulinumtoxin-A to abobotulinumtoxin-A in children with cerebral palsy treated for spasticity: a retrospective safety and efficacy evaluation. J Rehabil Med. 2019;51(5):390–394.
   PubMed Web of Science ®Google Scholar
• Eckwright D, Burke J, Gleason P. Real-world botulinum toxin (BT) utilization and treatment cost for cervical dystonia (CD) and limb spasticity (LS). AMCP Managed Care & Specialty Pharmacy Nexus Meeting; October 29–November 1, 2019, National Harbour, MD.
   Google Scholar
• Tapias G, Garcia-Romero M, Crespo C, et al. Cost-minimization analysis in the treatment of spasticity in children with cerebral palsy with botulinum toxin type A: an observational, longitudinal, retrospective study. Farm Hosp. 2016;40(5):412–426.
   PubMedGoogle Scholar
• Tedroff K, Befrits G, Tedroff CJ, et al. To switch from botox to dysport in children with CP, a real world, dose conversion, costeffectiveness study. Eur J Paediatr Neurol. 2018;22(3):412–418.
   PubMed Web of Science ®Google Scholar
• Ugrekhelidze DT, Kulikov AY. Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. Pharmacoeconom T&P. 2015;3(3):71–78.
   Google Scholar
• Misra VP, Danchenko N, Maisonobe P, et al. Economic evaluation of abobotulinumtoxinA vs onabotulinumtoxinA in real-life clinical management of cervical dystonia. J Clin Mov Disord. 2020;7(2):2–10.
   PubMedGoogle Scholar
• Misra VP, Colosimo C, Charles D, et al. INTEREST iN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin. J Neurol. 2018;265(2):402–409.
   PubMed Web of Science ®Google Scholar
• Ranoux D, Gury C, Fondarai J, et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry. 2022;72(4):459–462.
   Google Scholar
• Han Y, Stevens AL, Dashtipour K, et al. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia. J Neurol. 2016;263(4):772–780.
   Google Scholar
• Scaglione F. Conversion ratio between botox®, dysport®, and xeomin® in clinical practice. Toxins. 2016;8(3):65.
   PubMed Web of Science ®Google Scholar
• Evidente VG, Pappert EJ. Botulinum toxin therapy for cervical dystonia: the science of dosing. Tremor Other Hyperkinet Mov. 2014;4(0):273.
   PubMedGoogle Scholar
• Danchenko N, Whalen J, Burchakova M, et al. POSA121 modelling long-term outcomes and mortality risk for post-stroke spasticity patients on abobotulinumtoxina treatment and rehabilitation therapy. Value in Health. 2022;25(1):S57.
   Web of Science ®Google Scholar